Skip to content

Branched-Chain Amino Acid (BCAA) Catabolism

Summary

Branched-chain amino acid (BCAA) catabolism is the biochemical pathway that breaks down valine, leucine, and isoleucine into acyl-CoA derivatives for energy production. It consists of transamination catalyzed by branched-chain aminotransferases (BCAT1/2) followed by oxidative decarboxylation catalyzed by the branched-chain $\alpha$-keto acid dehydrogenase (BCKDH) complex. Large-scale genetic association studies have shown that common, low-frequency, and rare genetic variants converge on this pathway to regulate circulating BCAA levels, but genetic analyses suggest that therapeutically targeting this pathway to lower BCAAs is unlikely to reduce type 2 diabetes risk.

Biochemical Pathway

  1. Transamination: Valine, leucine, and isoleucine are converted to branched-chain $\alpha$-keto acids (BCKAs) by branched-chain aminotransferases, encoded by BCAT1 and BCAT2.
  2. Decarboxylation: BCKAs are decarboxylated by the BCKDH complex to form acyl-CoAs. The BCKDH complex is composed of:
  3. E1 subunit: Heterodimer of E1$\alpha$ (encoded by BCKDHA) and E1$\beta$ (encoded by BCKDHB).
  4. E2 subunit: Dihydrolipoyl transacylase (encoded by DBT).
  5. E3 subunit: Dihydrolipoyl dehydrogenase (encoded by DLD).
  6. Regulation: The BCKDH complex is regulated by:
  7. BCKDK: Branched-chain $\alpha$-keto acid dehydrogenase kinase, which phosphorylates and inactivates the BCKDH complex.
  8. PPM1K: Protein phosphatase 2Cm, which dephosphorylates and reactivates the complex.

A GWAS meta-analysis by Tambets et al. (2026) identified genetic associations at all six key genes in this pathway (BCAT2, DBT, PPM1K, DLD, BCKDHA, and BCKDK). Notable variants include: - A rare missense variant in BCKDHA (rs771686663 / 19-41414070-A-G, MAF = 0.012%), which is deleterious and associated with increased BCAA levels. - A rare splice region variant in BCKDK (rs118042732 / 16-31111297-T-A, MAF = 0.047%), which leads to splice acceptor loss and decreased BCAA levels. - A fine-mapped splice-disrupting variant in BCAT2 (rs48806519-G-C / 19-48806519-G-C, PIP = 1.0).

Although observational studies show strong associations between high BCAA levels and type 2 diabetes (T2D), cis-Mendelian Randomization targeting BCAT2, DBT, and PPM1K indicates a null effect on T2D and coronary artery disease (CAD), suggesting that lowering BCAAs via BCAA catabolism pathway activation does not reduce disease risk.

Citations

  • Mann, G. et al. (2021). Branched-chain amino acids: catabolism in skeletal muscle and implications for muscle and whole-body metabolism. Front. Physiol., 12, 702826.
  • Tambets, R. et al. (2026). Genetic analysis of circulating metabolic traits in 619,372 individuals. Nature. DOI: 10.1038/s41586-026-10532-5. Source paper: s41586-026-10532-5.pdf